AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00961194 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: Initial dosage: 250 mg/5 ml~Three doses of ketamine will be tested:~* 0.35 mg/kg~* 0.7 mg/kg~* 1.4 mg/kg Each patient will receive the indicated dose of oral ketamine or placebo once and if there are not adverse events, he will be able to continue the treatment three times a day, during 7 days (between visit 2 and 3).~The oral ketamine will be administered in form of syrup.
Study NCT03505528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanoparticle albumin-bound paclitaxel
Description: Abraxane is administered intravenous at a constant dose of 100mg/m2
Study NCT03505528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenelzine Sulfate
Description: Nardil is administered orally from a starting dose of 15mg/d to a maximum of 90mg/d
Study NCT02661074 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: A questionnaire will be completed in order to collect data on:~* Potential allergic manifestations after fish contact: asthma, allergic rhinitis, conjunctivitis, chronic or acute urticaria, dermatitis/eczema, or severe allergic manifestations (angioedema, bronchospasm, anaphylaxis),~* Occupational and/or domestic exposure to fish.
Study NCT00504894 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A low dose given intravenously one time for just under an hour while the subject is shown visually stimulating images in an MRI machine.
Study NCT00504894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: A low dose of propofol 0.90 μgml-1, given intravenously while the subject is shown visually stimulating images in an MRI machine.
Study NCT00504894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiopental
Description: A low dose of thiopental 3.0 μgml-1, given intravenously while the subject is shown visually stimulating images in an MRI machine.
Study NCT02492282 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-Loop propofol and remifentanil system by Bispectral Index
Study NCT02492282 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Open-Loop propofol and remifentanil by Target Controlled Infusion
Study NCT02492282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Study NCT02492282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Study NCT04858282 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobile application (BC-SDM)
Description: The mobile application (BC-SDM)includes four functions to support SDM activity: Understanding breast cancer, Surgical approach, Choose the right breast cancer knowledge, and Let's make a decision for myself. Patients first read the information in Understanding breast cancer and Surgical approach to receive a tailored education in breast cancer
Study NCT02841241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: Esmolol infusion
Study NCT01257022 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Familias Unidas
Description: There will be 8 group sessions and 4 family visits. During the group sessions, the facilitator offers support for parents and gently corrects maladaptive interactions between parents and adolescents. During family visits, facilitators assist families in practicing skills and restructuring family interactions. The parent group sessions focus on parental investment in the adolescent's worlds (e.g., peer and school worlds), family communication, family support, behavior management/positive parenting, parental monitoring, adolescent substance use, and adolescent unsafe sex and HIV.
Study NCT02262962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Redesigned Well-Child Care
Description: The Well-Child Visits will be enhanced using a newly-designed model of care. Parents will have access to Parent Coach during child's routine well visits, Well Baby Help Line, Well-Visit Planner, and HealthyTxt Messaging service.
Study NCT04328272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine 200 Mg Oral Tablet
Description: Hydroxychloroquine administered orally with water
Study NCT04328272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine 200 Mg Oral Tablet
Description: Hydroxychloroquine administered orally with water
Study NCT04328272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin 500Mg Oral Tablet
Description: Azithromycin administered orally with water
Study NCT04328272 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Glucose tablets
Description: administered orally with water
Study NCT03892135 — intervention group
Intervention type: OTHER
Intervention: Interviews with parents of children with juvenile idiopathic arthritis
Description: Interviews with parents of children with juvenile idiopathic arthritis
Study NCT03892135 — intervention group
Intervention type: OTHER
Intervention: Interviews with children with juvenile idiopathic arthritis
Description: Interviews with children with juvenile idiopathic arthritis
Study NCT03892135 — intervention group
Intervention type: OTHER
Intervention: Interviews with Physicians
Description: Interviews with Physicians
Study NCT00709410 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rBS-WC vaccine
Description: 1 mg of recombinant cholera toxin B subunit and approximately 1 x 10\^11 of inactivated whole cells of Vibrio cholerae O1 Inaba and Ogawa, classic and El Tor strains (6). The rBS-WC vaccine is supplied as 3 ml single-dose vials each with a sachet of sodium bicarbonate buffer. Buffer solution will be prepared by dissolving the sachets in drinking water (150 ml water for each sachet of sodium bicarbonate). The full dose of vaccine will be mixed with 40, 75, or 150 ml of buffer solution for persons 2 to 4 years, 5 to 11 years, and over 11 years old, respectively. The vaccine is recommended to be given in two doses with an interval of at least seven days and protection is conferred 7 to 10 days after the second dose.
Study NCT00768144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Study NCT01035944 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HemCon Dressings and HemCon ChitoGauze; chitosan-based.
Description: Perform debridement of chronic wounds using HemCon chitosan-based dressings and HemCon ChitoGauze both at bedside and in the Operating Room (OR) settings. Control for both settings will be gauze and saline dressings.
Study NCT03936972 — intervention group
Intervention type: PROCEDURE
Intervention: ilizarov circular frame and uni-planarexternal fixator
Description: both are types of external fixators, but one is circular frame and other is uni-planar frame
Study NCT05122429 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-Health Treatment
Description: Self-guided e-health treatment with two of the arms providing delayed (44min) text or video support from a therapist.
Study NCT01500304 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally invasive inguinal lymph node dissection
Description: Operative intervention will be a minimally invasive inguinal lymphadenectomy, which is a three trocar technique to the inguinal dissection, that respects the same anatomic boundaries as the conventional open procedure
Study NCT01211821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoprolol
Description: Tablets, Oral, 200 mg, once, 1 day
Study NCT01211821 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: metoprolol
Description: Tablets, Oral, 200 mg, once, 1 day
Study NCT01035944 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gauze and saline dressings.
Description: Control for both settings will be gauze and saline dressings.
Study NCT04089059 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cordella™ Pulmonary Artery Sensor System
Description: The Cordella PA Sensor System (CorPASS) is intended to measure, record, and transmit pulmonary artery pressure (PAP) data from NYHA Class III heart failure patients at home to clinicians for assessment and patient-centered heart failure management and comprises of seven subsystems that operate together to take daily Pulmonary Artery Pressure (PAP) readings at a patient's home and transmit the results to a care provider for evaluation.~1. Cordella Sensor~2. Cordella Delivery System~3. myCordella Patient Reader~4. Reader Dock~5. Cordella Calibration Equipment (CalEQ)~6. myCordella Hub~7. Cordella Data Analysis Platform (CDAP)
Study NCT01211821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-914392
Description: Tablets, Oral, 60 mg, once daily, 7 days
Study NCT03057782 — intervention group
Intervention type: DEVICE
Intervention: Waveguard (TM) EEG cap
Description: The device is an EEG cap - a non-invasive EEG positioning system used to quickly place a large number of surface electrodes in a quick and consistent manner on the head. The device will measure electrophysiological signals from the scalp at the time points in the study listed in the protocol.
Study NCT03057782 — intervention group
Intervention type: DEVICE
Intervention: Micro Movement Sensor
Description: This device is not FDA approved. This device is in clinical use for all age groups and used for research purposes by neurologists, physiologists and anesthesiologists. In this study, the device is used to monitor breathing and movement in children; the device is not used for validation purposes.
Study NCT03057782 — intervention group
Intervention type: DEVICE
Intervention: Pico Movement Sensor
Description: This device is not FDA approved. This device is in clinical use for all age groups and used for research purposes by neurologists, physiologists and anesthesiologists. In this study, the device is used to monitor respiration rate and gross body movement in children. The device will not be used for validation purposes.
Study NCT03057782 — intervention group
Intervention type: DEVICE
Intervention: QS Piezostimulator
Description: This device is not FDA approved. This device is used for research purposes by neurologists and physiologists. It is a mechanical tactile stimulator for use in functional imaging experiments like MEG, fMRI or EEG. The stimulation is realized by using several different pin matrices. In this study, the device is used to stimulate the children's extremities in order to elicit somatosensory evoked responses.
Study NCT03057782 — intervention group
Intervention type: DEVICE
Intervention: tactileTM sensory evaluator
Description: This device is not FDA approved. This device is used for clinical and research purposes by neurologists and physiologists. It is used to stimulate the children's extremities in order to elicit somatosensory evoked responses.
Study NCT04224506 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention for this study.
Study NCT03312205 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous CAR-T cells
Description: Patients will be drawn 50-100 ml blood to obtain enough peripheral blood mononuclear cells (PBMC) for CAR-T manufacturing. The T cells will be purified from the PBMC, transduced with CAR lentiviral vector, expanded in vitro and then frozen for future administration. Chemotherapy will then be given. Following tumor burden reassessment, CAR-T cells will be infused.
Study NCT00857974 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity
Description: The intervention is an individualized, structured, moderate intensity home-based physical activity program. During the first 12 weeks the program will focus on lower extremity strengthening, and thereafter incorporate cardiovascular activity. The target duration of activity is 150 minutes per week, i.e., 20-30 min on most days of the week. However, the program is adjusted based on each participant's progression, initial level of physical fitness and will be modified in response to illness, injury, or physical symptoms.
Study NCT02517320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-3995 Low
Study NCT02517320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-3995 Middle
Study NCT02517320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-3995 High
Study NCT02517320 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04939792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Capsules ingested orally
Study NCT04939792 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule ingested orally
Study NCT04939792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D + L-cysteine
Description: Capsule ingested orally
Study NCT04939792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-cysteine
Description: Capsule ingested orally
Study NCT05113992 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aromatherapy massage
Description: In the intervention group, 4% massage oil (3 ml jojoba fixed oil, 2% Frankincense and 2% Myrrh essential oil mixture) was applied on the skin on the forearm
Study NCT05113992 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: classic massage
Description: In the placebo massage group, jojoba fixed oil was applied to the skin on the forearm.
Study NCT02924012 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video game active
Description: The session lasted 40 minutes. The participants held an active video game session. At the end they were monitored for 60 minutes at rest.
Study NCT02924012 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: sedentary video game
Description: The session lasted 40 minutes. The participants held an sedentary video game session, using the traditional joystick. At the end they were monitored for 60 minutes at rest.
Study NCT02924012 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: walking
Description: The session lasted 40 minutes. The participants held a walk using the treadmill. At the end they were monitored for 60 minutes at rest.
Study NCT03507738 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MT-5625 low dose
Description: Intramuscular injection
Study NCT03507738 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MT-5625 middle dose
Description: Intramuscular injection
Study NCT03507738 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MT-5625 high dose
Description: Intramuscular injection
Study NCT03507738 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rotarix
Description: Oral administration
Study NCT03507738 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intramuscular injection
Study NCT02421679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNX-102 SL
Description: TNX-102 Sublingual tablets
Study NCT02458183 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV combination vaccine
Description: 0.5-mL IM
Study NCT02458183 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP vaccine and IPV vaccine
Description: 0.5-mL IM
Study NCT02237261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine, Bortezomib, Prednisone
Description: Cycle 1 (d1-42) - Induction:~Bortezomib: 1.3 mg/m2 s.c.: d1, 4, 8, 11, 22, 25, 29, 32 Bendamustine: 90 mg/m2 iv, d1, 2 Prednison: : 60 mg/m2 po,, d1-4~Cycle 2-9 (d1-28) - Consolidation:~Bortezomib: 1.3 mg/m2 s.c.: d1, 8, 15, 22 Bendamustine: 90 mg/m2 iv: d1, 2 Prednison: 60 mg/m2 po: d1-4
Study NCT02389439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyronaridine-artesunate
Study NCT00048100 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apheresis
Description: Apheresis for T-Cell collection
Study NCT00048100 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: Stem cell or marrow infusions of allogeneic donor lymphocytes activated by acute leukemia derived dendritic cells (DC/ADL).
Study NCT01973556 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist-Physician Collaborative Medication Therapy Management
Study NCT04368793 — intervention group
Intervention type: BEHAVIORAL
Intervention: Remote pulmonary rehabilitation
Description: The pulmonary rehabilitation intervention includes respiratory exercise, barehanded aerobic training, exercise prescription of elastic band impedance training, respiratory muscle strength training, etc.
Study NCT03067623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRP
Description: PRP intrauterine infusion
Study NCT03067623 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tomcat catheter
Description: PRP intrauterine infusion by means Tomcat catheter
Study NCT02670668 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mutation analysis
Study NCT02708355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg
Description: Esomeprazole 20 mg banded capsules (22.3 mg esomeprazole magnesium trihydrate)
Study NCT02708355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules
Study NCT02708355 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study NCT02034461 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Utah Slanted Electrode Array
Description: Microelectrode slanted arrays with a large number of electrodes will be surgically implanted into peripheral nerves of patients with limb amputations or peripheral nerve trauma.
Study NCT03254186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol Hydrochloride
Description: Propranolol is started 10 mg tablet twice per day per oral, two week up-titration to reach a total dose of 20mg per oral four times per day over the first two weeks, then will remain on a stable dose for six weeks.
Study NCT03254186 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Identical placebo is started one tablet twice per day per oral, increase over the first two weeks to reach one tablet four times per day, then will remain on this dose for six weeks.
Study NCT02664909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Study NCT02664909 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (saline)
Study NCT03214159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir Tablet 100mg
Description: Ritonavir Tablet 100mg is a generic product manufactured by Ascletis Pharmaceutical Co., Ltd.
Study NCT03214159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NORVIR tablet 100mg
Description: NORVIR Tablet is a generic product manufactured by AbbVie. NORVIR Tablet 100mg will be used as a comparator drug for the BE study.
Study NCT00323492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada
Description: Truvada + NNRTI or PI.
Study NCT03032549 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RTD
Description: Ready to Drink Supplement
Study NCT03032549 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02500446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dolutegravir
Description: Each film-coated tablet contains dolutegravir sodium equivalent to 50 mg dolutegravir.
Study NCT03647449 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Juice
Description: Participants will be drinking 800-900 kcal/day in cold-pressed juices.
Study NCT02500446 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A film-coated tablet identical in appearance to the active drug tablet but not containing any dolutegravir or any other active ingredient
Study NCT04147806 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IGRT 45 Gy in 5 fractions of 9 Gy
Description: Administration of 9 Gy in five consecutive days, to a total dose of 45 Gy radiation
Study NCT04147806 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IGRT 45 Gy in 5 fractions of 9 Gy
Description: Administration of 9 Gy in five consecutive days, to a total dose of 45 Gy radiation
Study NCT04147806 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IGRT 24 Gy single dose
Description: Administration of a single dose of 24 Gy in one session
Study NCT04147806 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IGRT 24 Gy single dose
Description: Administration of a single dose of 24 Gy in one session
Study NCT04147806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 4 mg by mouth on treatment days only
Study NCT04147806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 4 mg by mouth on treatment days only
Study NCT04147806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: 0.4 mg by mouth daily starting the day of simulation and until 2 weeks post-treatment.
Study NCT04147806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: 0.4 mg by mouth daily starting the day of simulation and until 2 weeks post-treatment.
Study NCT00235287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan and enalapril
Description: 24 weeks of treatment with Candesartan in incremental doses (4,8,16 mg), where Enalapril is added in incremental doses (5,10 and 20 mg)the last 8 weeks.
Study NCT00235287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: candesartan and enalapril
Description: 24 weeks of treatment with Enalapril in incremental doses (5, 10, 20 mg), where Candesartan is added in incremental doses (4,8,16 mg) in the last 8 weeks.